CING cingulate.com: מכפיל P/S עתידי

The forward P/S dynamics allow for a valuation of Cingulate Inc. (CING) based on synergies with research centers in the development of ADHD therapies. However, geopolitical logistics disruptions are hindering international trials, and a lack of internal cash flows leaves the company dependent on investments. Currently, this metric stands at , which helps objectively correlate market capitalization with expected revenue without reporting lags.

The licensing prospects for the CTX-1301 drug for ADHD therapy make the forward revenue multiple a key indicator of market expectations regarding the future cash flows of Cingulate Inc. (CING). This chart compares current market capitalization with expected forward sales, allowing investors to perform a real-time assessment of the premium for potential clinical success and the pace of business scaling.